Gastroesophageal Junction Adenocarcinoma Pipeline — VivoSeq

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Recruiting·National Cancer Center Hospital East·Phase 2·NCT07018570·26 enrolled

A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ATG-022 Compared With Investigator's Choice of Treatment in Subjects With Claudin18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·AAntengene Biologics Limited·Phase 3·NCT07795346·380 enrolled

Paclitaxel Oral Solution Plus Fruquintinib Versus Investigator's Choice as Second-Line Treatment for Advanced Gastric Cancer: A Multicenter, Open-Label, Randomized Controlled Trial

Recruiting·HHarbin Medical University·Preclinical·NCT07552402·150 enrolled

Post-marketing Observational Study of VYLOY (Zolbetuximab) Injection 100 mg, 300 mg for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in South Korea

Recruiting· Astellas logo

Astellas·N/A·NCT06902545·377 enrolled

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive

Recruiting· Astellas logo

Astellas·Phase 3·NCT06901531·500 enrolled

A Randomized, Open-label, Multicenter Phase III Clinical Study of QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic CLDN18.2-positive, PD-L1 CPS < 5 ，Her-2 Negtive Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07716449·560 enrolled

A Randomized, Double-blind, Multi-regional Phase 3 Study of Cadonilimab Combined With Chemotherapy Versus Chemotherapy in Combination With or Without Nivolumab for the First-line Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·AAkeso·Phase 3·NCT07700979·900 enrolled

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

Recruiting·PPhanes Therapeutics·Preclinical·NCT05482893·350 enrolled

A Phase I Trial of Perioperative FLOT(D) With Neoadjuvant Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Resectable Esophageal and Gastro-esophageal Junction Cancer

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT07700420·15 enrolled

A Prospective Single-arm Study Evaluating the Safety and Short-term Outcomes of Modular Robotic System for Siewert II/III Gastroesophageal Junction Cancer

Recruiting·TThe First Hospital of Jilin University·Preclinical·NCT07790809·25 enrolled

A Single-center, Prospective, Observational Cohort Study on the Effect of Different Digestive Tract Reconstruction Methods on Postoperative Quality of Life After Proximal Gastrectomy

Recruiting·TThe First Hospital of Jilin University·N/A·NCT06929949·90 enrolled

A Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Preclinical·NCT07643623·720 enrolled

A Randomized, Controlled, Multi-centers, Non Inferiority Phase II Clinical Study Comparing Iparomlimab and Tuvonralimab With Standard Chemotherapy Combined With PD-1/PD-L1 Monoclonal Antibody as First-line Treatment for MSI-H/dMMR Recurrent/Metastatic Gastric Cancer

Recruiting·PPeking University·Phase 2·NCT07127822·106 enrolled

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·AAntengene Biologics Limited·Preclinical·NCT07327229·132 enrolled

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: an Exploratory Study

Recruiting·RRuijin Hospital·Phase 2·NCT07384234·60 enrolled

Gastroesophageal Junction Adenocarcinoma

Pipeline Metrics

Competitive Landscape

Top Companies

Programs by Phase

Modality Breakdown

Trial Status

Trial Activity